Changeflow GovPing Pharma & Life Sciences

Recent changes

Favicon for www.pharmacy.ca.gov

California Board of Pharmacy Updates and AB 1503 Changes

The California Board of Pharmacy is updating its regulations effective January 1, 2026, due to Assembly Bill 1503. Key changes include a transition to a Standard of Care practice model for certain pharmacist-provided services and new requirements for nonresident pharmacies operating in California, effective July 1, 2026.

Priority review Guidance Pharmaceuticals
Favicon for www.pharmacy.ca.gov

California Board of Pharmacy Updates on SCRA, AB 1503, and Nonresident Pharmacies

The California Board of Pharmacy issued a news roundup detailing updates on the Servicemembers Civil Relief Act (SCRA), Assembly Bill 1503 impacting pharmacist practice, and new requirements for nonresident pharmacies. Key changes include the transition of certain pharmacist-provided patient care services to a standard of care model and new PIC designation rules for out-of-state pharmacies operating in California.

Priority review Notice Pharmaceuticals
Favicon for oig.hhs.gov

OIG Audit: Medicaid Agencies Made $207M in Unallowable Payments for Deceased Enrollees

The HHS OIG has released an audit report finding that Medicaid agencies made an estimated $207.5 million in unallowable capitation payments to managed care organizations on behalf of deceased enrollees between July 2021 and June 2022. The report recommends CMS provide agencies with data to recover payments and explore OBBB Act implementation.

Priority review Enforcement Healthcare
Favicon for oig.hhs.gov

Maine Medicaid Autism Services Improper Payments

The HHS OIG has issued a report finding that Maine made at least $45.6 million in improper fee-for-service Medicaid payments for autism services provided to children. The audit identified that all sampled claims were improper or potentially improper, leading to recommendations for refunds and improved provider guidance.

Priority review Enforcement Healthcare
Favicon for oig.hhs.gov

HHS OIG: ACF Can Improve Homeless Youth Services Compliance

The HHS Office of Inspector General (OIG) issued a report finding that the Administration for Children and Families (ACF) can improve services to homeless youth by strengthening grant recipients' compliance with Transitional Living Program (TLP) requirements. The audit found significant documentation gaps in service provision for a large percentage of youth served by TLP grants.

Priority review Guidance Social Services
Favicon for oig.hhs.gov

HHS OIG: Hospital Cybersecurity Controls Need Improvement

The HHS Office of Inspector General (OIG) issued a report finding that a large southeastern hospital needs to improve its cybersecurity controls, particularly for web applications. The OIG made four recommendations to enhance defenses against cyberattacks, which the hospital has concurred with.

Priority review Guidance Healthcare
Favicon for oig.hhs.gov

Philadelphia K-12 Schools COVID-19 Testing Program Audit

The HHS Office of Inspector General found that Philadelphia did not consistently monitor its COVID-19 screening testing program for K-12 schools, leading to $257,620 in unallowable costs and overpayments. The OIG recommended Philadelphia update its procedures for oversight and compliance.

Priority review Enforcement Public Health
Favicon for www.fda.gov

FDA Requests Removal of Suicidal Behavior Warning from GLP-1 RA Medications

The FDA is requesting that drug manufacturers remove the warning about suicidal ideation and behavior from the labeling of GLP-1 RA medications approved for weight reduction. This action follows a comprehensive review that found no increased risk associated with these drugs.

Priority review Guidance Pharmaceuticals
Favicon for www.gov.uk

MHRA Medical Devices Exceptional Use Authorisations List Updated

The UK's MHRA has updated its list of medical devices granted exceptional use authorisations. This guidance document provides transparency on manufacturers and devices that have received exemptions, including those whose authorisations have expired or been cancelled.

Routine Guidance Medical Devices
Favicon for www.gov.uk

MHRA: Stop using non-sterile alcohol-free wipes due to infection risk

The MHRA and UKHSA are advising the public not to use four specific non-sterile alcohol-free wipe products due to contamination with Burkholderia stabilis bacteria. These products have been withdrawn from sale, but may still be in homes, and are linked to 59 cases, including one death.

Urgent Guidance Product Safety

Showing 3901–3910 of 3,918 changes

1 389 390 391 392
RSS

Get daily alerts for pharma & life sciences

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

Filters

140 official sources tracked

Regs.gov: Food and Drug Administration

Updated 33m ago

USPTO Trademarks - Pharmaceuticals (Class 005)

Updated 11d ago

EPO Patent Bulletin - Therapeutics (A61P)

Updated 6m ago

USPTO Patent Applications - Pharma (A61K)

Updated 2d ago

USPTO Patent Applications - Biotech (C12N)

Updated 17h ago

ClinicalTrials.gov

Updated 2d ago

USPTO Patent Applications - Peptides (C07K)

Updated 2d ago

USPTO Patent Applications - Organic Chemistry (C07D)

Updated 4d ago

USPTO Patent Grants - Biotech (C12N)

Updated 12h ago

USPTO Patent Applications - Therapeutics (A61P)

Updated 2d ago

USPTO Patent Grants - Therapeutics (A61P)

Updated 3h ago

USPTO Patent Grants - Organic Chemistry (C07D)

Updated 12h ago

USPTO Patent Grants - Peptides (C07K)

Updated 7h ago

ANSM Drug & Device Safety Alerts

Updated 4m ago

FDA: Drug Recalls Class II

Updated 8d ago

FR: National Institutes of Health

Updated 5h ago

Health Canada Recalls & Safety Alerts

Updated 14h ago

Regs.gov: Centers for Medicare and Medicaid Services

Updated 22h ago

FR: Health and Human Services Department

Updated 5m ago

FR: Food and Drug Administration

Updated 5h ago

CPSC Product Recalls

Updated 13d ago

FR: Drug Enforcement Administration

Updated 12d ago

MHRA Guidance & Safety

Updated 32m ago

FDA Warning Letters

Updated 6d ago

FR: Centers for Disease Control and Prevention

Updated 1d ago

WHO News

Updated 3h ago

CMS Newsroom

Updated 5d ago

FR: Centers for Medicare & Medicaid Services

Updated 6m ago

Regs.gov: Occupational Safety and Health Administration

Updated 20h ago

DEA Press Releases

Updated 18d ago

DEA Public Safety Alerts

Updated 6d ago

Regs.gov: Animal and Plant Health Inspection Service

Updated 5d ago

HSA Singapore Announcements

Updated 8d ago

FDA Recalls & Safety Alerts

Updated 17h ago

FDA Medical Device Recalls

Updated 19m ago

Saudi SFDA News

Updated 21h ago

Regs.gov: Centers for Disease Control and Prevention

Updated 23h ago

HHS OIG Reports & Publications

Updated 12d ago

FR: Health Resources and Services Administration

Updated 6d ago

Regs.gov: Food Safety and Inspection Service

Updated 11d ago

FDA Press Releases

Updated 24h ago

NH Board of Pharmacy Actions

Updated 12d ago

FDA MedWatch Safety Alerts

Updated 21d ago

WV Board of Pharmacy

Updated 10d ago

USP Compendial Notices

Updated 12d ago

BfArM Drug Safety Communications

Updated 3d ago

MS Board of Pharmacy News

Updated 27d ago

FDA AI-Enabled Medical Devices

Updated 23d ago

LA Board of Pharmacy News

Updated 27d ago

FDA Guidance Documents

Updated 3h ago

ECHA News

Updated 14d ago

FDA Debarment List

Updated 9d ago

NICE Technology Appraisals

Updated 7d ago

FDA Drug Recalls Class I

Updated 19d ago

ANSM France News

Updated 10d ago

GA Board of Pharmacy Board Orders

Updated 22d ago

KS Board of Pharmacy Newsletters

Updated 20d ago

ID Board of Pharmacy

Updated 28d ago

USDA FSIS Recalls

Updated 14d ago

MHRA Drug & Device Alerts

Updated 7d ago

Frequently asked questions

What does this feed cover?

FDA warning letters, novel drug approvals, drug shortage notices, ICH guideline updates, USP notices, EMA news, DEA scheduling decisions, and TGA/WHO standards.

Who is this for?

Regulatory affairs professionals, pharmacovigilance teams, and medical affairs groups at pharma companies and CROs who need to track FDA and EMA actions.

How often is this updated?

GovPing checks source pages multiple times daily. FDA warning letters and drug approvals typically appear within hours of publication.

Does this cover EMA and international regulators?

Yes. We monitor the EMA, ICH, WHO, TGA (Australia), and other international health authorities alongside FDA.

How is this different from AgencyIQ?

AgencyIQ is a full FDA intelligence platform. GovPing is a free feed of the FDA, EMA, and ICH source pages where warning letters, approvals, drug shortages, and guidance are first published - AI-summarized with attention-level ratings on every change.

Is GovPing free?

Yes. GovPing is free, and always will be. We believe government regulatory data should be accessible to everyone. For custom monitoring of pages we don't cover yet, Changeflow starts at $99/mo.

Need to monitor something else?

GovPing covers the common sources. For niche pages specific to your team, add custom URL monitoring with Changeflow.

Get Pharma & Life Sciences alerts

Daily digest of pharma & life sciences regulatory changes. AI-summarized, no noise.

Free. Unsubscribe anytime.